Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01989689 · ClinicalTrials.gov registry record · Phase 2

Etanercept and Vascular Function in Psoriasis

A Phase 2 study, sponsored by Emory University.

Completed
Registry status
Phase 2
Development phase
24
Enrollment target

NCT01989689: Completed Phase 2 study, sponsored by Emory University.

NCT01989689 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01989689, a Phase 2 study, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target

Study Summary

The investigators plan to measure the health of the vascular system of subjects taking Etanercept for the treatment of plaque psoriasis.

Primary Outcome

Ultrasonography of the brachial artery performed at the bedside using a high-resolution 10-megahertz (MHz) ultrasound transducer before and after suprasystolic inflation of a blood pressure cuff for 5 minutes in the ipsilateral upper arm. Brachial artery FMD was calculated as (hyperemic diameter - baseline diameter)/baseline diameter × 100.

Interventions

  • DRUG Placebo
  • DRUG Etanercept

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2010-08
Est. Completion 2013-09
Phase Phase 2
Emory University

1,208 total trials

What the finished NCT01989689 record still lists

NCT01989689 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01989689 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01989689 about?

NCT01989689 is a clinical study titled "Etanercept and Vascular Function in Psoriasis". The investigators plan to measure the health of the vascular system of subjects taking Etanercept for the treatment of plaque psoriasis.

What is the current status of trial NCT01989689?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-08. Estimated completion is 2013-09.

What interventions are being tested in trial NCT01989689?

The interventions under investigation include: Placebo (DRUG), Etanercept (DRUG).

Who is sponsoring clinical trial NCT01989689?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01989689's enrollment target sits among peer trials

24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01989689, the US trial registry maintained by the National Library of Medicine. NCT01989689 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.